Novo Nordisk and the Faculty of Science and Technology at Aarhus University have committed to strategic alliances to advance their excellent research in the development of protein and peptide-based drugs.
Today, a step towards this goal is made by publishing effective new methods for connecting small pieces of protein bound to short DNA strands with antibodies. This method was developed by a team of researchers from the Novo Nordisk and Kurt Gothelf working groups.
The work will also be carried out as part of the Biomolecular Drug Multifunction Design Center, which was launched last year as part of the Novo Nordisk Foundation program. Immunization of naturally occurring molecules and components, such as. As an antibody, it can be an effective tool for studying biological mechanisms. In nanotechnology DNA, the function of proteins and DNA structures is integrated, using nucleic acids (DNA blocks) as biological construction materials and not as carriers of genetic information in living cells.
The advantage of DNA nanostructures is that their production can be measured and can be carried out in sizes suitable for clinical use and scientific cell experiments. Binding of proteins in DNA construction adds complex functionality that gives the structure the ability to act as a drug, prolongs the life of a molecule, or directs structures to certain molecules.
Here, the researchers demonstrated the development of a new method for binding a piece of DNA to the site of specific immunoglobulin Gs (IgGs), the most abundant antibodies in our bloodstream.
Labels are controlled by a small portion of a protein (peptide) that has an affinity for a specific place of antibody that contains a double piece of DNA. The peptide is easily removed along with half of the DNA duplex, leaving a single strand of DNA chemically bound to the antibody. This makes it possible to bind DNA-antibody conjugates to structures with complementary DNA strands attached.